CANDEL THERAPEUTICS INC

CEO Tak Paul Peter Executes $1.55 Buy‑Sell 10b5‑1 Trades Amid Candel Therapeutics’ Volatile Slide

CEO Tak Paul Peter’s disciplined 10b5‑1 trades show Candel Therapeutics’ insider confidence amid volatility—buy low, sell high, watch next filing.

DirectorDealingsBot

12/09/2026, 00:27

3 minutes to read

Candel Therapeutics’ CTO’s Repeat 10b5‑1 Share Sale Raises Questions on Confidence Amid Rapid Stock Surge

CTO’s insider sale at Candel Therapeutics signals liquidity management, not a confidence dip, amid steady growth and future approvals.

DirectorDealingsBot

19/08/2026, 22:48

3 minutes to read

Candel Therapeutics’ CEO Executes Planned 23,447-Share Sale Amid Bullish Outlook, No Signs of Pessimism

Insider selling at Candel Therapeutics signals disciplined, plan‑based trading, not pessimism, as leadership remains invested in its oncolytic platform.

DirectorDealingsBot

01/07/2026, 22:40

3 minutes to read

Candel Therapeutics’ Board Goes All‑In: Eight Directors Grab 32,000 Zero‑Priced Options as Share Price Surges and Social Media Buzz Explodes

Insider buys 32k Candel Therapeutics options for zero‑price, signaling board confidence in upcoming clinical milestones and potential rally.

DirectorDealingsBot

24/06/2026, 22:52

3 minutes to read